NovaBay Pharmaceuticals Inc (NBY) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
NovaBay Pharmaceuticals Inc stock (NBY) is currently trading at $1.42. NovaBay Pharmaceuticals Inc PE ratio is 0.05. NovaBay Pharmaceuticals Inc PS ratio (Price-to-Sales) is 2.94. Analyst consensus price target for NBY is $0.85. WallStSmart rates NBY as Sell.
- NBY PE ratio analysis and historical PE chart
- NBY PS ratio (Price-to-Sales) history and trend
- NBY intrinsic value — DCF, Graham Number, EPV models
- NBY stock price prediction 2025 2026 2027 2028 2029 2030
- NBY fair value vs current price
- NBY insider transactions and insider buying
- Is NBY undervalued or overvalued?
- NovaBay Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- NBY Piotroski F-Score and Altman Z-Score
- NBY analyst price target and Smart Rating
NovaBay Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
NBY Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · NovaBay Pharmaceuticals Inc (NBY)
NBY trades at a significant discount to its Graham intrinsic value of $175.44, offering a 100% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
NovaBay Pharmaceuticals Inc (NBY) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, profit margin. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
NovaBay Pharmaceuticals Inc (NBY) Key Strengths (2)
Keeps $32 of every $100 in revenue as net profit
Trading at 1.53x book value, attractively priced
Supporting Valuation Data
NovaBay Pharmaceuticals Inc (NBY) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -78.70%, a shrinking business
Very low institutional interest at 5.45%
Micro-cap company with very limited liquidity and high volatility
Revenue is fairly priced at 2.94x sales
Supporting Valuation Data
NovaBay Pharmaceuticals Inc (NBY) Detailed Analysis Report
Overall Assessment
This company scores 31/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Profit Margin, Price/Book. Valuation metrics including Price/Book (1.53) suggest the stock is attractively priced. Profitability is solid with Profit Margin at 31.50%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (2.94) suggest expensive pricing. Growth concerns include Revenue Growth at -78.70%, which may limit upside. Profitability pressure is visible in Return on Equity at -516.00%, Operating Margin at -224.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -516.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -78.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NBY Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NBY's Price-to-Sales ratio of 2.94x sits near its historical average of 3.33x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 22% below its historical high of 3.75x set in Mar 2026, and 0% above its historical low of 2.94x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~3.7x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for NovaBay Pharmaceuticals Inc (NBY) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
NovaBay Pharmaceuticals Inc faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 10M with 79% decline year-over-year. Profit margins are strong at 31.5%, reflecting pricing power and operational efficiency.
Key Findings
Revenue contracted 79% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact NovaBay Pharmaceuticals Inc.
Bottom Line
NovaBay Pharmaceuticals Inc faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(0 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 2:34:42 PM
About NovaBay Pharmaceuticals Inc(NBY)
NYSE MKT
HEALTHCARE
BIOTECHNOLOGY
USA
NovaBay Pharmaceuticals, Inc., a medical device company, develops products for the eye care markets in the United States and internationally. The company is headquartered in Emeryville, California.